A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial

Official title:

A Pilot, Double-blind, Placebo-controlled, 2-period Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02153489
• Other study ID #: M/34273/47
• Secondary ID: 2013-003373-10
• Status: Completed
• Phase: Phase 4
• First received: May 5, 2014
• Last updated: December 15, 2015
• Start date: April 2014
• Est. completion date: June 2015

Study information

• Verified date: December 2015
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of aclidinium bromide compared with placebo in improving dilatation of the airways (bronchodilation), symptoms of chronic obstructive pulmonary disease (COPD), sleep quality and physical activity after 3 weeks of treatment with aclidinium bromide 400 μg administered twice daily in patients with stable moderate-and-severe COPD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Adult male or non-pregnant, non-lactating female aged =40 years. Women of childbearing potential will follow specific study requirements (negative serum pregnancy test at the Screening Visit and are using, over the last two months before the Screening Visit, at least one medically approved and highly effective method of birth control

• Current or ex-cigarette smoker (patients who quit smoking more than 6 months prior to the Screening Visit), with a smoking history of at least 10 pack-years.

• Patients with a clinical diagnosis of chronic obstructive pulmonary disease (COPD) according to GOLD guidelines 2013, with a post bronchodilator FEV1 <80%, and FEV1 = 40% at Screening Visit

• Patients must be able to perform repeatable pulmonary function testing for FEV1 according to American Thoracic Society [ATS]/European Respiratory Society [ERS] 2005 criteria at Screening Visit

• Patients who are eligible and able to participate in the study and who consents to do so in writing after the purpose and nature of the investigation have been explained

Exclusion Criteria:

• History or current diagnosis of asthma

• Patients with moderate to severe sleep apnoea assessed at screening

• Patients who develop a respiratory tract infection or COPD exacerbation within 6 weeks (or 3 months if hospitalisation was required) before the Screening Visit (Visit 1) or during the run-in period

• Clinically significant respiratory conditions

• Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension

• Patients who may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to the Screening Visit

• Use of long-term oxygen therapy (15 hours/day)

• Patients who does not maintain regular day/night, waking/sleeping cycles including night shift workers

• Clinically significant cardiovascular conditions

• QTc >470 milliseconds in the manual ECG reading performed at Screening Visit

• Patients with clinically relevant abnormalities in the opinion of the investigator at the Screening Visit (Visit 1) in the results of the clinical laboratory tests, ECG parameters or in the physical examination)

• Patients with a history of hypersensitivity reaction to inhaled anticholinergics, long and short acting ß2-agonists, sympathomimetic amines, or inhaled medication or any component there of (including report of paradoxical bronchospasm)

• Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy

• Patients with known non-controlled history of human immunodeficiency virus (HIV) infection and/or active hepatitis

• History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer

• Patients with any other serious or uncontrolled physical or mental dysfunction, or moderate-to-severe depression, as confirmed by Beck Depression Inventory (BDI-II) total score >28.

• Patients with a history (within 2 years prior to the Screening Visit) of drug and/or alcohol abuse that may prevent study compliance based on investigator judgment

• Patients unlikely to be cooperative or that can't comply with the study procedures.

• Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to the Screening Visit

• Patients who intends to use any concomitant medication not permitted by this protocol or who have not undergone the required stabilization periods for prohibited medication

• Any other conditions that, in the investigator's opinion, might indicate the patient to be unsuitable for the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Aclidinium bromide

• Placebo

Locations

Country	Name	City	State
Germany	Pulmonary Research Institute at the Lung Clinic Grosshansdorf	Grosshansdorf
Germany	Pneumologische Lehrklinik der Universitätsmedizin Göttingen	Immenhausen

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24h Bronchodilation	Change from baseline in normalised forced expiratory volume in one second (FEV1).; FEV1 over the 24-hour period (AUC0-24) will be measured following morning administration	Week 3	No
Primary	Sleep Architecture	Apnoea/hypopnoea index (number of Apnoeas and Hypopnoeas in an hour of sleep) and total sleep time in minutes (sleep efficiency)	Week 3	No
Primary	Physical Activity	Change from baseline of the physical activity parameters including: steps per day, minutes of at least moderate activity (defined as any physical activity >3 metabolic equivalents)	Week 3	No
Primary	COPD Symptoms	Change from baseline in the average rating of overall early mornings and night-time COPD symptom severity	Week 3	No
Secondary	Adverse events	A follow up telephone call will be made 14 days after the last study drug administration (for completed patients) or premature discontinuation visit (when applicable) to record AEs	Week 5	Yes